AC220 and AraC cause differential inhibitory dynamics in patient-derived M5-AML with FLT3-ITD and, thus, ultimately distinct therapeutic outcomes

详细信息    查看全文

• 作者：Xiaoyu An^a ; Jinping Liu^a ; Na Wang^b ; Di Wang^b ; Liang Huang^b ; Likun Zhang^a ; Jie Cai^a ; Jean-Pierre Wery^a ; Demin Zhou^c ; Jianfeng Zhou^b ; Qi-Xiang Li^a ; ^c
• 刊名：Experimental Hematology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：45
• 期：Complete
• 页码：36-44.e2
• 全文大小：2345 K
• 卷排序：45

文摘

The first stable serially transplantable patient-derived xenograft of M5 acute myeloid leukemia in mice is described. Cytokines that support the autocrine mechanism for the growth of the implants were produced. This was the first patient-derived xenograft with both FLT3-ITD and IDH2 mutant acute myeloid leukemia. The drug effect in this model differed between chemotherapy standard of care and FLT target agent.